Skip to main content

Table 2 G6PD deficiency measured by the rapid diagnostic test CareStart™, and reactive G6PD enzyme activity of samples collected from RDT deficient individuals, measured by fluorescence spectrophotometry

From: Heterogeneity of G6PD deficiency prevalence in Mozambique: a school-based cross-sectional survey in three different regions

 

CareStart G6PD deficiency

Reactive G6PD activitya

Total

Deficient

% (95% CI)

χ2 test

p value

Total

Median U/gHg (range)

Kruskal–Wallis

p value

Pemba

 Females

509

33

6.5 (4.3–9.1)

0.03*

31

0.7 (0.2–0.7)

0.08*

 Males

386

41

10.6 (7.5–14.1)

40

0.7 (0.2–0.7)

 All

895

74

8.3 (6.5–10.1)

71

0.7 (0.2–0.7)

Mocuba

 Females

252

37

14.7 (10.3–19.1)

0.21*

33

1.4 (0.6–2.1)

0.08*

 Males

249

47

18.9 (14.0–24.1)

40

2.1 (0.6–2.1)

 All

501

84

16.8 (13.5–20.1)

73

1.4 (0.6–2.1)

Manhiça

 Females

390

55

14.1 (10.6–18.1)

0.65*

53

0.7 (0.5–2.5)

0.03*

 Males

240

37

15.4 (10.8–20.1)

36

0.6 (0.5–2.5)

 All

630

92

14.6 (11.8–17.1)

89

0.7 (0.5–2.5)

Total

 Females

1151

125

10.9 (9.1–13.1)

0.02δ

117

0.7 (0.2–2.5)

0.57δ

 Males

875

125

14.3 (12.0–17.1)

116

0.7 (0.2–2.5)

 All

2026

250

12.3 (10.9–14.1)

<0.001δ

233

0.7 (0.2–2.5)

<0.001δ

  1. * Chi Square or Kruskal–Wallis tests performed to assess the association between gender and G6PD Deficiency for each Area separately
  2. δChi Square or Kruskal–Wallis tests performed to assess the association between study area or gender and G6PD Deficiency Overall
  3. aREA assessed only for samples collected form G6PD Deficient Individuals as determined by the CareStart RDT
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us